{
    "clinical_study": {
        "@rank": "62151", 
        "acronym": "IVT", 
        "arm_group": [
            {
                "arm_group_label": "Nicardipine", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty"
            }, 
            {
                "arm_group_label": "Milrinone", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 2 : Milrinone, 5mg per circulation, intra-arterial injection, Pharmacological angioplasty"
            }, 
            {
                "arm_group_label": "Verapamil", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty"
            }, 
            {
                "arm_group_label": "Nicardipine + Verapamil + Nitroglycerin", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to determine the optimal intra-arterial drug therapy\n      and most effective treatment regiment for treating cerebral vasospasm following aneurysmal\n      subarachnoid hemorrhage. We hypothesize that combination of multiple drug agents infusion\n      (nicardipine +verapamil + nitroglycerin) will likely improve the treatment efficacy compared\n      to single agents (nicardipine or milrinone or verapamil).\n\n      All procedures done as a part of this study are standard hospital care procedures done to\n      treat cerebral vasospasm and all drugs to be used are FDA approved."
        }, 
        "brief_title": "The Intra-arterial Vasospasm Trial", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cerebral Vasospasm", 
        "condition_browse": {
            "mesh_term": "Vasospasm, Intracranial"
        }, 
        "detailed_description": {
            "textblock": "The primary objective of the study is to determine the optimal intra-arterial drug treatment\n      therapy regiment for treating cerebral vasospasm following aneurysmal subarachnoid\n      hemorrhage.\n\n      The secondary objective is to evaluate the functional clinical outcome post optimal\n      intra-arterial drug therapy for cerebral vasospasm following aneurysmal subarachnoid\n      hemorrhage.\n\n      This study is a multicenter randomized trial. The outcome variable to evaluate primary\n      objective is to measure the pre & post intra-arterial infusion blood vessel diameter in the\n      presenting vasospasmic blood vessel to measure the Post infusion improvement ratio (PIIR).\n      Modified Rankin score (mRs) at 3 months post hospital discharge will be recorded to study\n      the secondary objective for functional clinical outcome.\n\n      The interventions in this study trial are a part of standard hospital routine care\n      procedures for vasospasm treatment. Following surgical or endovascular intervention for\n      aneurysm rupture if patients develop cerebral vasospasm refractory to medical management\n      then endovascular treatment (intra-arterial FDA approved single agents or cocktail agents\n      drug infusion) will be initiated.\n\n      Study participants will be randomly assigned to one of the four treatment groups where one\n      single agent drug or cocktail agents will be intra-arterially administered. Pre & post\n      infusion vasospasmic vessel diameters will be compared. The change in diameter will be\n      quantified based on the mean percentage. Six weeks post hospital discharge study\n      participants will be followed up at clinic to evaluate functional outcome. The total\n      duration for study participation required is the standard hospital stay for post aneurysm\n      vasospasm treatment and one follow-up clinic visit at 3months.\n\n      The study will require 224 patients in total for 89% power to detect difference. Hence 28\n      subjects in total at each of the 8 participating centers will be enrolled. The patient\n      population will be hospitalized patients presenting with cerebral vasospasm post aneurysmal\n      subarachnoid hemorrhage.\n\n      Subjects will be stratified by randomization into 4 treatment groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patient, age 18-80 years old, with ruptured aneurysm(s) who experience cerebral\n             vasospasm post operatively within 3-21 days.\n\n        Exclusion Criteria:\n\n          -  Inability to obtain consent from patient or patients kin\n\n          -  Pregnant women\n\n          -  less than 18 years of age of more than 80 years of age"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996436", 
            "org_study_id": "IVT_201310 (HSC-MS-13-0586)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nicardipine", 
                "description": "Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm", 
                "intervention_name": "Nicardipine", 
                "intervention_type": "Drug", 
                "other_name": "Cardene"
            }, 
            {
                "arm_group_label": "Milrinone", 
                "description": "Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm", 
                "intervention_name": "Milrinone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Verapamil", 
                "description": "Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm", 
                "intervention_name": "Verapamil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nicardipine + Verapamil + Nitroglycerin", 
                "description": "Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm", 
                "intervention_name": "Nicardipine + Verapamil + Nitroglycerin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Verapamil", 
                "Nitroglycerin", 
                "Nicardipine", 
                "Milrinone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cerebral vasospasm", 
            "aneurysmal subarachnoid hemorrhage", 
            "intra arterial drug treatment for cerebral vasospasm", 
            "nicardipine milrinone nitroglycerin verapamil"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ketan.bulsara@yale.edu", 
                    "last_name": "Ketan R Bulsara, MD", 
                    "phone": "203-737-2096"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Ketan R Bulsara, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alaraj@uic.edu", 
                    "last_name": "Ali Alaraj, MD", 
                    "phone": "312-996-4842"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "University of Illinois College of Medicine at Chicago"
                }, 
                "investigator": {
                    "last_name": "Ali Alaraj, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lanzino.Guiseppe@mayo.edu", 
                    "last_name": "Guiseppe Lanzino, MD", 
                    "phone": "507-284-2511"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Guiseppe Lanzino, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "derdeync@mir.wustl.edu", 
                    "last_name": "Colin P Derdeyn, MD", 
                    "phone": "314-362-5580"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine in St. Louis"
                }, 
                "investigator": {
                    "last_name": "Colin P Derdeyn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "adnan.h.siddiqui@gmail.com", 
                    "last_name": "Adnan H Siddiqui, MD", 
                    "phone": "716-218-1000"
                }, 
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14203"
                    }, 
                    "name": "University of Buffalo"
                }, 
                "investigator": {
                    "last_name": "Adnan H Siddiqui, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Pascal.Jabbour@jefferson.edu", 
                    "last_name": "Pascal M Jabbour, MD", 
                    "phone": "215-955-7000"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Thomas Jefferson University"
                }, 
                "investigator": {
                    "last_name": "Pascal M Jabbour, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ducruetaf@upmc.edu", 
                    "last_name": "Andrew F Durcruet, MD", 
                    "phone": "412-864-1839"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh Medical Center"
                }, 
                "investigator": {
                    "last_name": "Andrew F Ducruet, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "peng.r.chen@uth.tmc.edu", 
                    "last_name": "Peng R Chen, MD", 
                    "phone": "713-704-7100"
                }, 
                "contact_backup": {
                    "email": "Aditya.A.Sanzgiri@uth.tmc.edu", 
                    "last_name": "Aditya A Sanzgiri, MBBS MPH", 
                    "phone": "713-704-7263"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas Medical School at Houston"
                }, 
                "investigator": {
                    "last_name": "Peng R Chen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "The Intra-arterial Vasospasm Trial- A Multi-center Randomized Study", 
        "other_outcome": {
            "description": "Intra-cranial pressure will be measured 1 day prior to vasospasm treatment and 1 day after vasospasm treatment", 
            "measure": "Intra-cranial pressure", 
            "safety_issue": "No", 
            "time_frame": "1 day prior to procedure & 1 day after the procedure"
        }, 
        "overall_contact": {
            "email": "Peng.R.Chen@uth.tmc.edu", 
            "last_name": "Peng R Chen, MD", 
            "phone": "713-704-7100"
        }, 
        "overall_contact_backup": {
            "email": "Aditya.A.Sanzgiri@uth.tmc.edu", 
            "last_name": "Aditya A Sanzgiri, MBBS, MPH", 
            "phone": "713-704-7100", 
            "phone_ext": "7263"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Texas Medical School at Houston", 
                "last_name": "Peng R Chen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yale School of Medicine", 
                "last_name": "Ketan R Bulsara, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Post infusion improvement ratio(PIIR) = (B - A) / A\nA = pre-infusion blood vessel diameter B = post infusion blood vessel diameter\nPIIR across all four treatment arms will be compared and tested for statistical significance.", 
            "measure": "Post infusion improvement ratio(PIIR)", 
            "safety_issue": "No", 
            "time_frame": "pre pharmacological angioplasty blood vessel diameter - 0 min, post pharmacological angioplasty blood vessel diameter- 10 min after infusion"
        }, 
        "reference": [
            {
                "PMID": "18638721", 
                "citation": "Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci. 1994 Jan;1(1):19-26."
            }, 
            {
                "PMID": "12744357", 
                "citation": "Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003 May;98(5):978-84. Review. Erratum in: J Neurosurg. 2003 Dec;99(6):1119."
            }, 
            {
                "PMID": "3176090", 
                "citation": "Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke. 1988 Oct;19(10):1300-5."
            }, 
            {
                "PMID": "3895589", 
                "citation": "Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985 Jul-Aug;16(4):562-72. Review."
            }, 
            {
                "PMID": "18312091", 
                "citation": "Keuskamp J, Murali R, Chao KH. High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008 Mar;108(3):458-63. doi: 10.3171/JNS/2008/108/3/0458."
            }, 
            {
                "PMID": "19057319", 
                "citation": "Linfante I, Delgado-Mederos R, Andreone V, Gounis M, Hendricks L, Wakhloo AK. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery. 2008 Dec;63(6):1080-6; discussion 1086-7. doi: 10.1227/01.NEU.0000327698.66596.35."
            }, 
            {
                "PMID": "15140728", 
                "citation": "Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, Rordorf GA. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004 May;25(5):819-26."
            }, 
            {
                "PMID": "20098322", 
                "citation": "Pierot L, Aggour M, Moret J. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care. 2010 Apr;16(2):110-6. doi: 10.1097/MCC.0b013e3283372ef2. Review."
            }, 
            {
                "PMID": "18239182", 
                "citation": "Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008 Mar;39(3):893-8. doi: 10.1161/STROKEAHA.107.492447. Epub 2008 Jan 31."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996436"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center, Houston", 
            "investigator_full_name": "Peng Roc Chen", 
            "investigator_title": "Assistant Professor - Neurosurgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Clinical outcome at 6 weeks post discharge from hospital after treatment will be evaluated using Modified Rankin score", 
            "measure": "To grade clinical outcome using Modified Rankin score", 
            "safety_issue": "No", 
            "time_frame": "6 weeks post discharge from hospital"
        }, 
        "source": "The University of Texas Health Science Center, Houston", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Yale University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Washington University School of Medicine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University at Buffalo", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Thomas Jefferson University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Illinois at Chicago", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mayo Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Pittsburgh", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "The University of Texas Health Science Center, Houston", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}